Key Decisions in HIV Care

Download All
Expert international faculty present biweekly Medical Minute updates with downloadable slides and podcasts on emerging data guiding key decision points in HIV care focused on the individual patient. ClinicalThought commentaries from both patients and healthcare professionals highlight unique patient needs and how best to address them.
Latesha Elopre, MD, MSPH
Joseph J. Eron, Jr., MD
Jason Halperin, MD, MPH
Daniel R. Kuritzkes, MD
person default
Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
person default
Anonymous Patient

Prevention

Learn how to initiate PrEP in underserved communities, with examples on overcoming barriers and improving access.

Latesha Elopre, MD, MSPH Released: June 7, 2021

Listen as Latesha Elopre, MD, MSPH, explains how to initiate PrEP in underserved communities, with examples on overcoming barriers and improving access.

Latesha Elopre, MD, MSPH Released: July 7, 2021

See how to initiate PrEP in underserved communities, with examples on overcoming barriers and improving access.

Latesha Elopre, MD, MSPH Released: June 7, 2021

Switch Strategies

In this concise presentation, Dr. Daniel Kuritzkes discusses recent data on new long-acting injectable ART.

Daniel R. Kuritzkes, MD Released: May 19, 2021

In this on-demand recording of a live webinar, expert faculty discuss important considerations when switching ART in patients with viral suppression on their current regimen, including guideline recommendations and data supporting different switch regimen options such as single-tablet triple therapy, 2-drug oral regimens, doravirine-based regimens, and long-acting injectable therapy.

Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: June 10, 2021

Learn key considerations when selecting a new ART regimen for patients with viral suppression who need a change in HIV treatment. Topics include weighing the pros and cons of switching to contemporary 3-drug therapy regimens, oral 2-drug options, and long-acting injectable 2-drug regimens.

Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: June 7, 2021

Listen as Daniel R. Kuritzkes, MD, explains key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure.

Daniel R. Kuritzkes, MD Released: July 7, 2021

See key clinical trial data and practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure.

Daniel R. Kuritzkes, MD Released: June 4, 2021

Learn why one patient feels that long-acting ART gave her a lot of her life back.

person default Anonymous Patient Released: September 16, 2021

ART Initiation

In this case example, learn whether weight gain should or should not be a factor in determining initial therapy.

Joseph J. Eron, Jr., MD Released: July 22, 2021

In this case example, learn the importance of timely initiation of ART for an adolescent patient.

Jason Halperin, MD, MPH Released: September 10, 2021

In this case example, learn the importance of initiation of treatment for OUD along with ART initiation

Jason Halperin, MD, MPH Released: September 10, 2021

Listen as Joseph J. Eron, Jr., MD, explores whether weight gain should or should not be a factor in determining initial therapy.

Joseph J. Eron, Jr., MD Released: August 30, 2021

See whether weight gain should or should not be a factor in determining initial therapy.

Released: August 2, 2021

My advice for other young people with HIV is just to start medications and be honest with yourself. You’ll feel much better knowing you’re doing something about it now rather than waiting.

person default Anonymous Patient Released: September 7, 2021

Learn why addressing OUD along with ART is such an important key decision in HIV care.

person default Anonymous Patient Released: September 8, 2021

Special Populations

In this case example, learn the latest data about whether to use tenofovir alafenamide during pregnancy.

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: September 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue